Table 3.
Efficacy of atezolizumab according to clinical/pathological parameters in randomized trials
| Clinical/pathological parameters | OAK triala,4,21 II–III line (1,225 pts), Phase III | POPLAR triala,19 II line (287 pts), Phase II | IMpower150 trialb,24 I line (800 pts), Phase III | IMpower131 trialc,27 I line (1,021 pts), Phase III |
|---|---|---|---|---|
| ECOG performance status | ||||
| 0 | 37% (HR 0.80)d | 32% (NA) | 41% (HR 0.55) | 33% (HR 0.68) |
| 1 | 63% (HR 0.77) | 68% (NA) | 58% (HR 0.64) | 67% (HR 0.70) |
| Age | ||||
| <65 years | 54% (HR 0.84)d | NA | 54% (HR 0.65) | 48% (HR 0.77) |
| ≥65 years | 46% (HR 0.69) | NA | NA | NA |
| 65–74 years | NA | NA | 36% (HR 0.52) | 41% (HR 0.66) |
| 75–84 years | NA | NA | 9% (HR 0.78)c | 11% (HR 0.51) |
| Sex | ||||
| Male | 62% (HR 0.79) | 59% (NA) | 61% (HR 0.55) | 82% (HR 0.71) |
| Female | 38% (HR 0.81)d | 41% (NA) | 39% (HR 0.73) | 18% (HR 0.66) |
| Smoking | ||||
| Current/previous smoker | 83% (HR 0.78) | 81% (HR 0.75)d | 84% (HR 0.58) | 92% (HR 0.70) |
| Never smoker | 17% (HR 0.91)d | 19% (HR 0.55)d | 16% (HR 0.80)d | 8% (HR 0.77)d |
| Liver metastases | ||||
| Yes | NA | NA | 14% (HR 0.54)* | 20% (HR 0.77)d |
| No | NA | NA | 86% (HR 0.63) | 80% (HR 0.68) |
| Brain metastases | ||||
| Yes | 10% (HR 0.59) | NA | NA | NA |
| No | 90% (HR 0.82) | NA | NA | NA |
| Histology | ||||
| Squamous | 74% (HR 0.79) | 34% (HR 0.66)d | NAe | NAf |
| Non-squamous | 26% (HR 0.79)d | 66% (HR 0.69) | ||
| Molecular status | ||||
| EGFR mutation | 9% (HR 1.19)d | 7% (NA) | NA | NA |
| EGFR wild type | 75% (HR 0.76) | 51% (NA) | NA | NA |
| KRAS mutation | 7% (HR 0.82)d | 9% (NA) | 12% (HR 0.50) | NA |
| KRAS wild type | 24% (HR 0.93)d | 16% (NA) | 18% (HR 0.47) | NA |
| KRAS unknown | 69% (HR 0.76) | 75% (NA) | 71% (HR 0.67) | NA |
| ALK translocation | 0.4% (NA) | 1% (NA) | NA | NA |
| ALK wild type | 49% (NA) | 40% (NA) | NA | NA |
| EGFR/ALK alteration | NA | NA | 13% (HR 0.54)d,* | NA |
| EGFR/ALK wild type | NA | NA | 87% (HR 0.62) | NA |
Notes:
The hazard ratios of OAK and POPLAR studies refer to overall survival.
Hazard ratios of comparison between arms B (atezolizumab + bevacizumab + chemotherapy) and C (bevacizumab + chemotherapy) only. The hazard ratios of IMpower150 study refer to progression-free survival for all parameters, with the exception of “Liver metastases – yes” and “EGFR/ALK alteration” the hazard ratios of which refer to overall survival (*).
Hazard ratios of comparison between arms B (atezolizumab + chemotherapy) and C (chemotherapy) only. The hazard ratios of IMpower131 study refer to progression-free survival.
Confidence intervals of hazard ratio through the unit.
Only patients with non-squamous histology were enrolled in IMpower150 study.
Only patients with squamous histology were enrolled in IMpower131 study.
Abbreviations: NA, not available; pts, patients.